let's bring in meg terrell. we've seen this happen before. >> that's very true.is really cool graphic we showed earlier in the day and i like it so much, i want to show it again, if we can. which compares the first three months of 2014 with the first three months of 2015 for biotech and we see a very, very similar pattern. it looks like the run-up and drop-off this year was a little bit steeper, because the sell-off start earlier in the first quarter last year, but we've seen this before. and in previous sell-offs, the losing evacuates this year, we've seen a four-day losing streak that ended february 4th. that was tied to gilead forecasting bigger than expected discounts on its hepatitis "c" drugs. but last year you saw these sell-offs, and in the middle of the year, around janet yellkin's comments, we saw another sell-off. and toward the end of the year when express scripts came out, people started worry again. so often these events will lead to a few day sell-off in biotech. right now, there's no similar event that led to this. it could be the end of the first

the battle against alzheimer's disease and it has sent biogen stock through the roof today. >> meg terrelluraging data up here for the drug. >> sara that's right. if you look at bye-bye biojen stock, closing up 10%. they surpassed some very high expectations on the study. the results coming out showed strong sighs of efficacy in clearing the amyloid plaques and in slowing the cognitive declines you see in memory and thinking clearly that are hallmarks of alzheimer's. people are excited about those particularly since we have seen to many failures. safety is also key. one of the things that doctors are pointing out the side effect that was seen in some of the higher doses of the drug. so now the question becomes can the company find the right dose to take it forward and we should potentially see more data on that later this year. the company is moving very quickly into the latest phases of clinical trials into a phase three study directly from phase one. so that's important. they're really speeding this along here. analysts say it's still a long road, still very risky going into phase three

meg terrell is here with us to go through the story.y. >> before the break you were mentioning intercept, which was up based on its competitor's data. that competitor is genfit. it plunged 44%. near traded in paris. i just got off the phone with the ceo who told me he thinks the market is really overreacting here. he is actually calling the phase two study a success. now, what happened was it missed its top line goal and when they took out some early stage patients with this early liver disease called nash, what they found is that in high risk patients, the drug appeared to be working, and so that's why they're calling it success, and they're going forward into a phase three trial. we also mentioned -- the drug looks very safe he said and it looks to be cardio protective, lowering the levels of bad cholesterol, raising the levels of high -- of good cholesterol in the blood. we also talked about the future of the company. he says they plan to list on nasdaq this year. they also need to raise some money in order to go into that phase thre

meg terrell with the stocks to watch coming out of the conference, meg? >> it's a big show down in cholesterol drugs. we show you about the $10 billion new class of therapies plus more stocks that may be on the move monday. next. now with the xfinity tv go app, you can watch live tv anytime. it's never been easier with so many networks all in one place. get live tv whenever you want. the xfinity tv go app. now with live tv on the go. enjoy over wifi or on verizon wireless 4g lte. plus enjoy special savings when you purchase any new verizon wireless smartphone or tablet from comcast. visit comcast.com/wireless to learn more. >>> dollar general says it will spend more on labor. this is coming as a reaction to the tightening in the low labor market. following walmart's decision to raise wages. revlon gets half of its sales outside of the u.s. >>> the clothing retailer buckle is reporting a 4.3% growth. online sales up 12.6%. sarah? >> all right. a rare bright spot, tyler, in today's market. the german dax now at record highs. one way to play germany's blue c

here is meg terrell with more. >> how fast are drug prices rising? pharmacy benefits manager express scripts says the increases are setting records. express scripts negotiated drug prices on behalf of insurers. it says the gains were driven by a 31% increase in the cost of so-called specialty drugs like those for rheumatoid arthritis, cancer multiple sclerosis, and hepatitis c. >> it's not sustainable pricing. so we have to do something to both bring the products to the marketplace but also make it affordable for patients. >> the drug price war came to a head last year over a revolutionary new pill for hepatitis c. it costs upwards of $80,000 for 12 weeks of treatment, drawing resistance from insurers and patient advocacy groups. when it was approved in december express scripts struck an exclusive deal and then gilead reached a similar deal with cvs, forcing it to make a 40% discount on the pills this year. express script says it's not finished. next up, maybe a new class of drugs for cholesterol, expected to be approved later this year. cvs has esti

our meg terrell checks the pain points plus the pros will be weighing in on what you should be doing.maybe is it time to buy the biotech dip or not? >> and up next is it apple pay or apple pray? one analyst claims as much as 6% of apple pay transactions is done using stolen credit cards. is it that high? we'll get both sides when we come back. we come back. hello. i am here to offer sophisticated investing strategies. my technology can help you choose the right portfolio. monitor it. and automatically rebalance it. all without charging advisory fees, account service fees or commissions. that may be hard to compute. but i'm a computer. so trust me. it computes. say hello at intelligent.schwab.com ♪ ♪ ♪ (under loud music) this is the place. ♪ ♪ ♪ their beard salve is made from ♪ ♪ ♪ sustainable tea tree oil and kale... you, my friend, recognize when a trend has reached critical mass. yes, when others focus on one thing test test+++@ test test test test >>> big moves today. the dow down 221 points here. look at the nasdaq. down almost 100 points, almost a 2% decline. biotech a big part o

joining us now in a cnbc exclusive is spark's ceo, jeff marrazzo and we brought along meg terrell.rs. >> thank you. so we were just talk about companies that have to sales and $2 billion market caps and you're $1.8 billion, no sales yet. let's get to valuations in a bit, but i want to start by what you do. your ticker is once, so you're in gene therapy. what is that? >> well, genes ultimately play this role as a blueprint in underlying how cells function. so the concept is actually that you take a normal copy of a gene or a healthy copy of gene and you bring it to those patients' cells and by doing so, you're able to potentially correct the underlying basis of the disease. so the idea is that if you can deliver that to the patient, there's a potential for the patient to then correct what they need to do on potentially on a long-lasting basis if not on a curative basis that's the promise behind gene therapy. if you think of what we're doing in a first area that we're working in is is this area of inherited blindness. where there's more than 200 different genes that account play a ro

let's bring in cnbc biotech reporter meg terrell and, meg, we started talking about the last week. "wall street journal" today. it's reached mainstream media essentially. now wha? >> that's right. if you are looking at the biotech index, everything is red today. if you look at the biggest names, amgen, celegene and biogen. it's the smaller names that you have highlighted a lot that are seeing the biggest losses today. novavax, newly genetics and leading the index lower. other names really we're just hearing about a lot of fear in the space. this three-day losing streak is the longest for the nasdaq biotech index since february 4th. i've been talking with a lot of investors, a lot of industry folks just about what's going on here. is this a bubble? are we seeing the end of it? are we seeing the end of the rapid rise? the nasdaq biotech index over the last five years is up 280%. this is really go go go. what a lot of people are saying is this is a lot of fear coming in. this is three days this week. then it's been bad. that's playing in here. a lot of other folks say it's about wheth

meg terrell is life in key west florida, with that story. >> we'll tell you why they're on guard here in key west. >> i don't want my people to have -- be bitten or to have mosquitos. it's like hide and seek every day. just because i'm away from my desk doesn't mean i'm not working. comcast business understands that. their wifi isn't just fast near the router. it's fast in the break room. fast in the conference room. fast in tom's office. fast in other tom's office. fast in the foyer [pronounced foy-yer] or is it foyer [pronounced foy-yay]? fast in the hallway. i feel like i've been here before. switch now and get the fastest wifi everywhere. comcast business. built for business. >> on deck for the next hour. with so much talk of bubbles in stocks, we dig into a potential trouble spot in a totally different market. plus, the good the bad, and the down right ugly on this march to nasdaq 5,000, and a helping healthy dash of good news. why the so-called misery index is not living up to its name. thankfully. back to you, guys. sfwroo see you at

meg terrell, a big play here on pharma benefits.harmacy benefit managers, what they do in part is negotiate drug prices on behalf of health insurers and unh is a health insurer, and it's consolidate, but it owned its own benefits manager. what i'm hearing from people today is this is further consolidation in this industry giving these pbm's a lot more power. we're even seeing them use this power on drug prices. the biggest pharmacy benefits are now express scripps, cvs, and united health combined with catamaran. there are a couple of implications on the deal here. express scripps -- it's not just combined with a health insurer or pharmacy which cvs is combined with. will we see a potential combination there for express scripps? the second is on drug companies stocks because if these pbm's get more and more powerful as they get bigger at the top as this deal does they're going to get more drug pricing negotiation power which we've seen play out in hepatitis c. >> clearly, the scale helps. what you are saying is there are not a lot of

. >>> with the dow up about 47 points, meg terrell joins us tracking some of the movers this monday.shares of herbalife are soaring for a second straight day up 7% now following on friday's 10% gain and last week a federal judge dismissed a lawsuit brought by herbalife shareholders alleged the company is a pyramid scheme. starbucks is announcing its baristas will no longer be asked to write race together on cups given to customers. the ceo says the coffee chain will continue other aspects of its campaign aimed at sparking discussions on race. >> we're going to talk about that a little bit more right now, meg. race in america, a difficult but important issue, and one that starbucks ceo howard schultz wanted to tackle head on in a campaign that would have had his coffee baristas discussing racial issues openly with customers. he explained his thinking last week on cnbc to our jim cramer during "mad money." >> all we're trying to do is potentially do something catalytic to start a conversation. we don't want to be intrusive on any level. we're simply trying to raise the awareness, the l